Relmada Therapeutics Q3 net loss widens on higher R&D costs
RLMD•Relmada Therapeutics reported a third-quarter net loss of $13.9 million, or $0.12 per share, as research and development costs rose. It ended the quarter with $202.1 million in cash and expects the funds to cover operations through 2029.
1. Quarterly results
Relmada Therapeutics’ third-quarter net loss widened to $13.9 million, with a loss of $0.12 per share. Research and development expenses rose due to higher study and manufacturing costs, including preparations for NDV-01 and sepranolone studies.
2. Pipeline and cash
The company ended the quarter with $202.1 million in cash and expects it to fund operations through 2029. Relmada expects to submit an IND for NDV-01 by year-end 2026 and plans to start the Phase 3 SPECTRUM program after IND clearance.
